國家衛生研究院 NHRI:Item 3990099045/14962

NHRI > Institute of Biomedical Engineering and Nanomedicine > Jen-Kun Chen > Periodical Articles > Item 3990099045/14962

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/14962

Title:	Using precise boron neutron capture therapy as a salvage treatment for pediatric patients with recurrent brain tumors
Authors:	Chen, YW;Lan, TL;Lee, YY;Lin, KH;Liang, ML;Chen, HH;Pan, PS;Chang, FC;Wu, CC;Lin, SC;Kang, YM;Lee, JC;Liu, HM;Chen, KH;Chen, JK;Lin, CF;Kuo, YC;Hsu, SM;Huang, WS;Chou, FI
Contributors:	Institute of Biomedical Engineering and Nanomedicine
Abstract:	Background: Boron neutron capture therapy (BNCT) is a precise targeted particle therapy. Its principal purpose is to specifically administer boron-10-containing drugs to tumor cells and subsequently irradiate them with thermal neutrons. This highly explosive tumor destruction method exclusively attacks tumor cells that uptake boron-10-containing drugs, while minimizing damage to the surrounding normal cells without drug uptake, thereby making it an ideal option for the precise treatment of pediatric patients with recurrent brain tumors. Methods: Since March 2017, Taipei Veterans General Hospital collaborated with the Nuclear Science and Technology Development Center of National Tsing-Hua University to develop a salvage BNCT for recurrent tumors in the central nervous system. BNCT was delivered to patients using the research reactor of Tsing-Hua University. As of January 2020, a total of nine BNCT treatments (10 sites) have been performed on five pediatric patients with recurrent brain tumors. Results: The diagnoses of all five patients were recurrent glioblastomas, two of which developed from the brainstem. The median follow-up duration was 5.3 months. After BNCT, one site had complete response, and three had partial response. The median progression-free interval was 3.8 months. None of the five patients showed severe normal brain tissue necrosis nor serious complications after treatment. Conclusions: Pediatric patients are a vulnerable group with medical needs that are distinct from those of adult patients. BNCT is a precise cancer treatment for pediatric recurrent brain tumors with less normal toxicities and high tumor response.
Date:	2020-12-30
Relation:	Therapeutic Radiology and Oncology. 2020 Dec 30;4:Article number 6521.
Link to:	http://dx.doi.org/10.21037/tro-20-20
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85129028197
Appears in Collections:	[Jen-Kun Chen] Periodical Articles

Files in This Item:

File	Description	Size	Format
SCP85129028197.pdf		643Kb	Adobe PDF	94	View/Open

Loading...